Filtry
Erdoxaban in clinical trials and in the clinical practise
Edoxaban - a direct inhibitor of factor Xa - has a confirmed anticoagulant and antiaggregatory effect and is available in doses 15, 30, and 60 mg. Edoxaban showed a decrease% (p < 0,001 for non-inferiority) on high dose edoxaban...
FA - Kardiovaskulární nemoci včetně kardiochirurgie
- 2016 •
- Jx •
- Odkaz
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
Edoxaban versus warfarin in patients with atrial fibrillation
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk...
FA - Kardiovaskulární nemoci včetně kardiochirurgie
- 2013 •
- Jx •
- Odkaz
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
Edoxaban - new FXa inhibitor
Edoxaban is a next new oral direct inhibitor of F Xa. The article presents overview of its effect compared to warfarin in the prevention of ischemic stroke. Edoxaban is now registered for both of these indications in the Czech Repub...
Hematology
- 2017 •
- Jost
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Edoxaban
Edoxaban is included in the group of vitamin K-independent anticoagulants. Its anticoagulant effect is mediated by factor Xa inhibition. Efficacy and safety of edoxaban were tested in three important comparative clinical studies: in...
Cardiac and Cardiovascular systems
- 2017 •
- Jost
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Edoxaban - pharmacological profile
Edoxaban is a direct inhibitor of factor Xa in the coagulation cascade. The efficacy and safety of edoxaban compared to warfarin was presented in the large indication for edoxaban is the treatment of deep vein thrombosis, p...
Cardiac and Cardiovascular systems
- 2017 •
- JSC
Rok uplatnění
JSC - Článek v periodiku v databázi SCOPUS
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Aims Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted edoxaban therapy in patients undergoing AF to assess the safety and efficacy of once-daily edoxaban 60 ...
Cardiac and Cardiovascular systems
- 2019 •
- Jimp •
- Odkaz
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Edoxaban - its properties and role in antithrombotic prophylaxis in atrial fibrillation
Anticoagulation is an integral part of comprehensive care of patients with atrial fibrillation. In addition to vitamin K antagonists (VKA) used for years, more recently novel anticoagulant drugs have been increasingly prevailing, with edoxaban
Cardiac and Cardiovascular systems
- 2018 •
- JSC •
- Odkaz
Rok uplatnění
JSC - Článek v periodiku v databázi SCOPUS
Výsledek na webu
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
) patients undergoing ablation with uninterrupted edoxaban or vitamin K antagonist (VKA) therapy. Methods and results: Patients were randomized 2:1 to once-daily edoxaban 60 ablation (edoxaban n = 375; VKA n = 178). The med...
Cardiac and Cardiovascular systems
- 2021 •
- Jimp •
- Odkaz
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Edoxaban
Blocade of factor Xa becomes a routine part of clinical praxis instead of coumarine blockade with warfarin, providing a more benfitial and safer effect. The main indiactions are nonvalvular atrial fibrillation, deep venous trombosis, lung embolism an...
Cardiac and Cardiovascular systems
- 2018 •
- JSC
Rok uplatnění
JSC - Článek v periodiku v databázi SCOPUS
Edoxaban for the treatment of cancer-associated venous thromboembolism
by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutaneous%) in the edoxaban group as compared with 71 of the 524 patients (13.5%) in the dalteparin group patients (7.9%) in the edoxaban group...
Cardiac and Cardiovascular systems
- 2018 •
- Jimp •
- Odkaz
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
- 1 - 10 z 70